# EDGAR Filing Document

**Accession Number:** 0001857044
**File Stem:** 0001829126-25-010296
**Filing Date:** 2025-12
**Character Count:** 5868
**Document Hash:** 97d92e3b1f58fcea642fc5d3714b85c2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001829126-25-010296.hdr.sgml**: 20251223

**ACCESSION NUMBER**: 0001829126-25-010296

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251222

**FILED AS OF DATE**: 20251223

**DATE AS OF CHANGE**: 20251223

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Lazar David E.
- **CENTRAL INDEX KEY:** 0001932843

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40652
- **FILM NUMBER:** 251602114

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 44, TOWER 100, THE TOWERS
- **STREET 2:** WINSTON CHURCHILL, PAITILLA
- **CITY:** PANAMA CITY
- **PROVINCE COUNTRY:** R1
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Indaptus Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001857044
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 863158720
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 3 COLUMBUS CIRCLE
- **STREET 2:** 15TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** (646) 427-2727

**MAIL ADDRESS:**
- **STREET 1:** 3 COLUMBUS CIRCLE
- **STREET 2:** 15TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Intec Parent Inc.
- **DATE OF NAME CHANGE:** 20210414

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Lazar David E.<br><sub>(Last) (First) (Middle)</sub><br>44, TOWER 100, THE TOWERS WINSTON<br>CHURCHILL, PAITILLA<br><sub>(Street)</sub><br>PANAMA CITY, R1 07196<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Indaptus Therapeutics, Inc. [ INDP ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-12-22 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Co-Chief Executive Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 0<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Series AA Convertible Preferred Stock<sup>(2)</sup> | 2025-12-22 | <sup>(3)</sup> | Common Stock | 6000000 | <sup>(4)</sup> | D |  |
| Series AAA Convertible Preferred Stock<sup>(2)</sup> | 2025-12-22 | <sup>(3)</sup> | Common Stock | 105000000 | <sup>(4)</sup> | D |  |

---

### Footnotes:

(1) No shares of Common Stock are beneficially owned.

(2) On December 22, 2025, David E. Lazar (the "Reporting Person") and Indaptus Therapeutics, Inc. (the "Company"), entered into a securities purchase agreement pursuant to which the Reporting Person acquired (i) an aggregate of 300,000 shares of the Company's Series AA Convertible Preferred Stock (the "Series AA Preferred Stock") at a price of $6.00 per share and (ii) an aggregate of 700,000 shares of the Company's Series AAA Convertible Preferred Stock (the "Series AAA Preferred Stock", and together with the Series AA Preferred Stock, the "Preferred Stock") at a price of $6.00 per share. Each share of Series AA Preferred Stock is convertible into 20 shares of the Company's Common Stock at any time, subject to certain ownership limitations. Each share of Series AAA Preferred Stock is convertible into 150 shares of the Company's Common Stock at any time, subject to certain ownership limitations.

(3) The Preferred Stock is perpetual and therefore has no expiration date.

(4) The shares of Preferred Stock are convertible at the option of the Reporting Person for no additional consideration

**Remarks:**
No securities are beneficially owned.

**Signature:** /s/ David E. Lazar  
**Date:** 2025-12-23

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**